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1. INTRODUCTION 
The liver is a major detoxifying organ in the body. It is also one of the largest organs 
in the human body and is a intense site for metabolism. It has a major role in the 
maintenance, performance and regulation of homeostasis of the body. It is involved with 
almost all the biochemical pathways responsible for growth, nutrient supply, energy 
provision and reproduction. The major functions of the liver are carbohydrate, protein and fat 
metabolism, detoxification, secretion of bile and storage of vitamins. 
 
 
Figure . 1 Functions of liver 
 
           Liver diseases are posing as a major health problem around the world. Toxic industrial 
chemicals, alcohol, viral infection, water pollutants and aflatoxins are major risk factors of 
liver disease
1
.  
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         There are more than a hundred kinds of liver diseases, some of the most common ones 
are
2
, 
1. Hepatitis, inflammation of the liver, is caused by various viruses (viral hepatitis) liver 
toxins (e.g. alcoholic hepatitis), autoimmunity (autoimmune hepatitis) or hereditary 
conditions. 
2. Alcoholic liver disease is a hepatic manifestation of alcohol over consumption. It 
includes fatty liver disease, alcoholic hepatitis and cirrhosis.  
3. Fatty liver disease is a reversible condition where large vacuoles of triglyceride fat 
accumulate in liver cells. 
4. Non-alcoholic fatty liver disease is a spectrum of disease associated with obesity and 
metabolic syndrome. 
5. Hereditary diseases that cause damage to the liver include hemochromatosis, 
involving accumulation of iron in the body. 
6. Gilbert’s syndrome, a genetic disorder of bilirubin metabolism found in a small 
percent of the population, can cause mild jaundice. 
7. Cirrhosis is the formation of fibrous tissue (fibrosis) in the place of liver cells that 
have died due to a variety of causes, including viral hepatitis, alcohol over 
consumption and other forms of liver toxicity. Cirrhosis causes chronic liver failure. 
8. Autoimmune disorders Sometimes the immune system may begin to attack the liver 
or bile ducts causing inflammation and scarring which leads to a progressive form of 
liver disease. Examples of liver diseases believed to be caused by the immune system 
are primary biliary cirrhosis (PBS), primary sclerosing cholangitis (PSC) and 
autoimmune hepatitis. 
9. Fascioliasis, a parasitic infection of liver caused by a Liver fluke of the Fasciola 
genus, mostly the Fasciola hepatica. 
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 Along with the major health complications such as cancer, respiratory diseases, 
cardiovascular diseases, the incidence of liver disease is also on the rise along with the 
growing population. It is a major cause of death increasing every year and it is the fifth big 
killer in countries such as England and Wales.  
 
According to the latest WHO data published in May 2014, liver disease deaths in India 
reached 216,865 or 2.44% of total deaths
3
. The worldwide death from cirrhosis and liver 
cancer is 50 million per year. 1.3 million deaths worldwide are due to chronic viral hepatitis. 
The harmful use of alcohol results in 2.5 million deaths worldwide each year with over 5,000 
deaths in England and Wales in each of the last ten years
4
. Statistics obtained from birth and 
death registration department of Pune Municipal Corporation, India showed that an average 
of 35-40 people die every month from liver related problems. Contrary to popular belief, even 
non-alcoholics can fall to deadly liver diseases. Alcohol abuse continues to cause maximum 
cases of liver cirrhosis
 5
. 
 
CAUSES OF LIVER DAMAGE
6, 7 
     Chemical induced liver damage: Carbon tetrachloride, alcohol consumption, aflatoxins,                   
     1, 1, 2, 2- tetrachloroethane, carbon tetrabromide, dimethyl formamide,  
     ethylene dichloride. 
     Alcohol abuse 
     Drug induced: More than 900 drugs have been implicated in causing liver injury and it is  
     the most common reason for a drug to be withdrawn from the market. Drug induced liver     
     injury is responsible for 5% of hospitalised persons and 50% of all acute liver failures.  
     Some of them are Acetaminophen over dose, Amiodarone, Ketoconazole, Rifampicin,    
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     Virus induced: Hepatitis A, B, C, D and E.  
     Other causes: Non-alcoholic fatty liver, malnutrition, extrahepatic infections, ingestion of  
     poisonous wild mushrooms, haemochromatosis. 
 
PATHOPHYSIOLOGY OF LIVER DAMAGE 
The hepatocellular stress induced by hepatotoxins or by viruses may lead to the 
activation of liver resident macrophages on one side and to the release of chemokines on 
other side. Proinflammatory cytokines are Interleukins-1β, Interferon-gamma (IFN-γ), whose 
tissue concentration increases early after toxins administration, followed by Tumor Necrosis 
Factor- , Interleukin-6 in a similar kinetics, which are released by natural killer cells as well 
as kupffer cells. 
 
 
 
Figure. 2 Pathophysiology of liver damage 
They induce an increase expression of cell adhesion molecules like ICAM-1 and 
VCAM-1 on the portal or sinusoidal endothelial cells and a down regulation of PECAM 
1.These molecules allow the recruitment and sinusoidal transmigration of inflammatory cells 
toward their target, the hepatocyte. 
Inflammation perpetuates as long as damaging noxae remain present or are repeatedly 
administered. Leukocytes may enter the liver tissue mainly enter the portal tract, where the 
inflammation mainly initiates
8
. 
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MECHANISM OF LIVER DAMAGE
7, 9 
75% of blood coming to the liver arrives directly from gastrointestinal organs and 
then spleen via portal veins that bring drugs and xenobiotics in near-undiluted form. Several 
mechanisms are responsible for either inducing hepatic injury or worsening the damage 
process. Many chemicals damage mitochondria, an intracellular organelle that produces 
energy. Its dysfunction releases excessive amount of oxidants that, in turn, injure hepatic 
cells. Activation of some enzymes in the cytochrome P-450 system such as CYP2E1 also 
leads to oxidative stress.
 
Injury to hepatocyte and bile duct cells lead to accumulation of bile 
acid inside the liver. This promotes further liver damage. Non-parenchymal cells such as 
Kupffer cells, fat storing stellate cells, and leukocytes (i.e. neutrophil and monocyte) also 
have a role in the mechanism. 
Immune mechanisms involve cell cooperation and are mediated by cytokines, nitric 
oxide and complement. Pathologic apoptosis is potentially an important mechanism of acute 
liver injury. Specific attention is paid here to the more frequent causes of acute liver failure, 
hypoxia/reoxygenation, liver congestion, acetaminophen poisoning, posttransplant acute liver 
rejection, severe sepsis, viral hepatitis, and alcoholic liver disease. Knowledge of the intimate 
mechanisms of liver injury at the cellular level may lead to adaptation of therapeutic 
strategies that will prevent end-stage liver failure. 
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STAGES OF LIVER DAMAGE 
 
 
 
Figure. 3 Stages of liver damage 
  
SIGNS AND SYMPTOMS OF THE LIVER DISEASE
9, 10 
         Symptoms partly depend on the type and the extent of liver disease. In many cases, 
there may be no symptoms. Signs and symptoms that are common to a number of different 
types of liver disease include, 
 Jaundice or yellowing of the skin  
 Darkened urine  
 Nausea, vomiting  
 Loss of appetite  
 Unusual weight loss or weight gain  
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 Diarrhoea  
 Light-coloured stools  
 Abdominal pain in the upper right part of the stomach  
 Generalized itching  
 Varicose veins (enlarged blood vessels)   
 Hypoglycaemia (low blood sugar)  
 Muscle aches and pains  
 Depression  
 
RISK FACTORS 
A number of factors increase the risk of developing liver disease, which can lead to liver 
failure. Risk factors include, 
 Alcoholism 
 Coronary artery disease (due to atherosclerosis or hardening of the arteries, or other 
causes) 
 Diabetes  
 Exposure to certain toxins, such as arsenic 
 Exposure to hepatitis 
 High triglyceride levels in the blood 
 Long-term treatment with corticosteroids 
 Obesity 
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DIAGNOSIS 
A healthcare professional can determine whether a person symptoms, medical history, 
and physical exam are consistent with liver disease. Hepatomegaly, an enlarged, firm liver, 
and other signs of liver disease may be found on examination. 
 
Many further tests may also be used to support the diagnosis. These include blood tests, 
such as 
 Liver function tests, which are blood tests that check a wide variety of liver enzymes 
and by products. 
 A complete blood count (CBC), which looks at the type and number of blood cells in 
the body. 
 Abdominal X-rays. 
 Ultrasounds, to show size of abdominal organs and the presence of masses. 
 An upper GI study, which can detect abnormalities in the oesophagus caused by liver 
disease. 
 Liver scans with radio tagged substances to show changes in the liver structure. 
 ERCP or Endoscopic Retrograde Cholangio Pancreatography. A thin tube called an 
endoscope is used to view various structures in and around the liver.  
 Abdominal CT scan or abdominal MRI, which provide more information about the 
liver structure and function. 
 
In some cases, the only way to definitively diagnose the presence of certain liver diseases 
is by a liver biopsy. This procedure involves the removal of a tiny piece of liver tissue for 
examination under a microscope. Liver biopsies may have to be done repeatedly to see how 
the disease is progressing or responding to treatment. 
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Some of the drugs currently available in the management of liver disease are, 
1) Ursodeoxycholic acid (Ursodiol) 
Mechanism of action 
It is more hydrophilic and hepatotoxic than the major circulating bile acids in humans. 
The immunomodulatory effects of Ursodeoxycholic acid are to involve decreased 
immunoglobulin production by B lymphocytes, decreased interleukin-1 and interleukin-2 
production by T lymphocytes, decreased expression of hepatocyte cell surface membrane 
HLA Class I molecules and possibly stimulation of the hepatocyte glucocorticoid receptor. 
Clinical applications 
Ursodeoxycholic acid has been used in the management of chronic hepatic diseases in 
humans such as primary biliary cirrhosis, biliary disease secondary to cystic fibrosis, non-
alcoholic steatohepatitis, idiopathic chronic hepatitis, autoimmune hepatitis, primary 
sclerosing cholangitis, and alcoholic hepatitis. 
Dose rate 
It is recommended that Ursodeoxycholic acid be administered for 3-4 months after 
which the patient should be reassessed for improvement in biochemical markers of 
hepatocellular pathology. If there has been improvement, treatment is continued, but if there 
has been no improvement or progression, either treatment should be terminated or additional 
therapies such as glucocorticoids or colchicine added. 
Adverse effects 
           Diarrhoea, Vomiting 
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2) Penicillamine 
Penicillamine is a degradation product of penicillin but has no antimicrobial activity. 
It was first isolated in 1953 from the urine of a patient with liver disease who was receiving 
penicillin. 
Penicillamine is a monothiol chelating agent which is used in veterinary medicine in 
the treatment of copper-storage hepatopathy (e.g. Bedlington Terriers), lead toxicity and 
cystine urolithiasis. It has also been used in the management of rheumatoid arthritis and 
Wilson’s disease. 
Dosage and formulations 
             For management of copper-associated hepatopathy, a dose of 10–15 mg/kg q12h p.o 
is given. 
Adverse effects 
 GIT adverse effects are common resulting in nausea and vomiting. Smaller doses on a 
more frequent basis may alleviate adverse effects. Alternatively, the drug can be given 
with food although this will reduce absorption. 
Other adverse effects observed infrequently or rarely include, 
 Fever 
 Lymphadenopathy 
 Skin hypersensitivity reactions 
 Immune-complex glomerulonephropathy 
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Other drugs include 
Liver disease treatment will depend on the type and the extent of disease. For 
example, treating hepatitis B, hepatitis C and hepatitis D may involve the use of medications 
such as the antiviral medication alpha interferon. Other medications used to treat liver disease 
may include ribavirin, lamivudine, steroids and antibiotics. 
 The currently available drugs, though useful, are also associated with side effects. 
 
IMPORTANCE OF HERBS IN TREATING LIVER DISORDER 
Herbal medicines are in great demand in the developed world due to their efficacy, 
safety and lesser side effects. Herbal drugs are most widely used than allopathic drugs as 
hepatoprotective because they are inexpensive, have better cultural acceptability, better 
compatability with the human body and minimal side effects. 
A number of plants and traditional formulations are available for the treatment of liver 
diseases. Around 170 phytoconstituents isolated from 110 plants belonging to 55 families 
have been reported to possess hepatoprotective activity
11
. It is estimated that about six 
hundred (600) commercial herbal formulations are used world over as hepatoprotective 
drugs. 
Amongst the many plants that have hepatoprotective activity, Silymarin is widely 
used as a hepatoprotectant around the world. It is a mixture of flavanoid complexes and is the 
active component of milk thistle plant that protects liver and kidney cells from toxic effects 
of drugs, including chemotherapy
12
. Silymarin is composed of a mixture of four isomeric 
flavonolignans: silibinin, isosilibinin, silydianin and silychristin. Silymarin possesses free 
radical scavenging ability, it increases antioxidant enzymes, such as superoxide dismutase 
(SOD) and catalase and inhibits lipid peroxidation. It is reported to offer protection against 
various chemical hepatotoxins such as CCl4 and alcoholic liver. 
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  Many plants like Solanum xanthocarpum, Adiantun incisum, Ardisis solanacea 
Parmelia perlata, etc. have been reported to possess hepatoprotective activity against CCl4 
induced hepatotoxicity. Some lichens like Usnea ghattensis have been reported to contain 
antioxidant and hepatoprotective activity against ethanol induced liver damage
13
. 
          
  There are many plants which have not been subjected to a through scientific 
evaluation. One such plant is Pongamia pinnata L., In this plant the leaves and stem bark 
have been studied and they are known to possess hepatoprotective activity. These are rich in 
flavonoids such as furanoflavones, furanoflavonols, chromenoflavones, furanochalcones and 
pyranochalcones and it consist of several flavone and chalcone derivatives such as Pongone, 
Galbone, Pongagallone A and B
14
. The presence of flavonoids has been reported as the 
reason for their hepatoprotective activity.  
 
The seeds have not been so far subjected to hepatoprotective activity screening. The 
seeds of Pongamia pinnata L., are also rich in flavonoids. Hence the present study was 
carried out to explore the hepatoprotecive efficacy of seeds of Pongamia pinnata L., against 
CCl4 induced hepatotoxicity in rats model. 
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2. REVIEW OF LITERATURE 
 
 
2.1. PHARMACOLOGICAL STUDIES 
 
 Kaur et al., 2014 evaluated the hepatoprotective activity of the ethanolic and aqueous 
stem bark extract of Pongamia pinnata L., against paracetamol induced hepatotoxicity. 
The efficacy of protection was measured by evaluation of biochemical parameters, 
such as SGOT (Serum glutamate oxalate transaminase), SGPT (Serum glutamate 
pyruvate transaminase), ALP (Alkaline phosphatase) and total bilirubin levels, as well 
as in vivo estimation of GSH (Glutathione) from liver tissue. The results were 
observed that the activity of SGOT, SGPT, ALP and total bilirubin was reduced in 
extract treated rats as compared to the disease control group rats
15
. 
 
 Digamber R et al., 2013 investigated Pongamia pinnata L., for its antifungal 
properties using different plant parts –leaves, bark, roots and seeds. The seeds of 
plants possessed highest antifungal activity followed by roots, bark and least activity 
was observed in the leaves. Epidermophyton floccosum was most susceptible to all the 
extracts closely followed by Candida albicans indicating the susceptibility to the 
components of the extracts. Helminthosporium turcicum was most resistant to all the 
extracts closely followed by Alternaria solani indicating the resistance to plant 
originated chemicals being familiar to such chemicals
16
. 
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 Selvaraju Kavipriya et al., 2013 studied the antidiabetic activity of methanolic 
leaves extract of Pongamia pinnata L., with the dosage of 500mg/kg and 1g/kg was 
carried out in experimental animals. When the dosage level increased to 1g/kg, results 
revealed higher increment when compared to 500mg/kg. The methanolic leaf extract 
showed significant anti-hyperglycaemic activity at higher dose 1g/kg
17
. 
 
 Divya Singh et al., 2013 studied the anti-inflammatory and anti-arthritic activity of 
seed extract of Pongamia pinnata L., by in vitro model. Pongamia pinnata L., hydro 
alcoholic extract exhibited a concentration dependent inhibition of protein (albumin) 
denaturation. The stabilization of HRBC membrane showed a concentration 
dependent anti-inflammatory activity and the protection increased with increase in the 
concentration of the Pongamia pinnata L., hydroalcoholic extract
18
. 
 
 SR Arote et al., 2012 evaluated the hepatoprotective activity of the methanolic extract 
of Pongamia pinnata L., against paracetamol induced liver damage in rats. In vitro 
estimation of antioxidant activity was carried out using two different methods i.e.by 
hydroxyl radical scavenging activity and total reduction capability. The different 
doses (100, 200, 400 mg/kg) of the methanolic extract of Pongamia pinnata L., were 
screened for hepatoprotective and antioxidant activity. The AST, ALT, ALP values 
were significantly reduced in pre-treatment with methanolic extract of Pongamia 
pinnata L., group. It was also found that the methanolic extract of Pongamia pinnata 
L., showed dose dependant hydroxyl radical scavenging activity and total reduction 
capacity
19
. 
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 S. Aneela et al., 2011 have reported the acute toxicity studies of crude seed extract of 
Pongamia pinnata L., in female Albino Wistar rats. The studies included the gross 
observation such as changes in body weight and food intake. The rats treated with 
dose of 2000mg/ kg body weight were safe
20
. 
 
 In a study by Jimidi Bhaskar et al., 2011the methanol extracts of leaves of Pongamia 
pinnata L., produced significant (P<0.01) anti-pyretic activity. The 200mg/kg extracts 
has shown a good anti-pyretic effect (P<0.01) when compared to the control group. 
The results obtained indicate that the crude leaf extracts of Pongamia pinnata L., 
possess potent anti-pyretic activity
21
. 
 
 The anticonvulsant effect of 70% ethanol extract of Pongamia pinnata L., leaf against 
pentylene tetrazole induced convulsion (PTZ) in rats was evaluated by Ashish 
manigauha et al., 2010. The ethanolic extract showed significant anticonvulsant 
activity by lowering the duration of extension phase (3.72± 0.65) when compared to 
control group (8.94 ± 0.42). Investigation of the anticonvulsant efficacy of 70% 
ethanol leaf extract of Pongamia pinnata L., using maximal electroshock-induced 
seizure (MES) in mice showed significant anticonvulsant activity characterised by of  
lowering the duration of extension phase (4.12 ± 0.67) when compared to control 
group (9.64 ± 0.41). These results indicate the potential anticonvulsant activity of the 
leaves of Pongamia pinnata L.,
22
. 
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 The anti-hyperglycaemic and anti-lipidperoxidative activity of flowers of Pongamia 
pinnata L., were carried out by Punitha et al., 2006. The oral administration of 
ethanolic extract of Pongamia pinnata L., flower shows significant anti-
hyperglycaemic and anti-lipidperoxidative effect and also enhance antioxidant 
defense system in alloxan-induced diabetic rats
23
. 
 
 Essa et al., 2006 have evaluated the hepatoprotective effects of ethanolic extract of    
Pongamia pinnata L., leaves in ammonium chloride induced hyperammonimia in rats. 
It was reported that the ethanolic extract offered protection against hepatotoxicity 
induced by Ammonium chloride by influencing the levels of lipid peroxidation 
products and liver marker enzymes. This activity is mediated by the antioxidant 
property of the leaf extract of Pongamia pinnata L.,
24
. 
 
 Brijesh et al., 2006 have reported the anti-microbial effect of crude leaf extract of 
Pongamia pinnata L., and have evaluated its effect on production and action of 
enterotoxins. Its extraction has no anti-bacterial, anti-giardial and anti-viral activities 
but reduces the production of cholera toxin and bacterial invasion to epithelial cells. 
This indicates that the extract of Pongamia pinnata L., has selective anti-diarrhoeal 
action with efficacy against cholera
25
. 
 
 Ethanolic extract of flowers of Pongamia pinnata L., was studied for its protective 
effect against cisplatin and gentamicin induced renal injury in rats Shirwaikar et al., 
2004. When the extract (300 & 600 mg/kg) was administered orally for 10 days 
following cisplatin (5 mg/kg, i.p.) on day 5, the flowers of Pongamia pinnata L., had 
a protective effect against cisplatin and gentamicin induced renal injury. The possible 
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mechanism of its protective effect against nephrotoxicity was attributed to its 
antioxidant activity
26
. 
 
 Prabha et al., 2003 have reported that the methanolic extract of Pongamia pinnata 
L., roots showed significant protection against aspirin and has a tendency to decrease 
acetic acid-induced ulcer after 10-days treatment. By augmentation of mucosal 
defensive factors like - mucin secretion, life span of mucosal cells, mucosal cell 
glycoproteins, cell proliferation and prevention of lipid peroxidation, the extract also 
shows ulcer protective effect
27
. 
 
 Uddin et al., 2003 investigated the antifilarial potential of the fruits and leaves 
extracts of Pongamia pinnata L., on cattle filarial parasite. In their investigation, the 
aqueous and alcohol extracts of fruits and the alcohol extract of leaves caused an 
inhibition of spontaneous movements of the whole worm and the nerve-muscle 
preparation of Setaria. cervi. The concentration required to inhibit the movements of 
the whole worm preparation was 250μg/mL for aqueous, 120μg/mL for alcohol 
extract of fruits and 270μg/mL for alcohol extracts of the leaves. The concentrations 
of Pongamia pinnata L., extracts required to produce an equivalent effect on the 
nerve-muscle preparation were 25μg/ml, 5μg/ml and 20μg/ml28. 
 
 Srinivasan et al., 2003 evaluated the analgesic activity of the various root extracts of 
Pongamia pinnata L., The petroleum ether extract (PEE), n-Butanol extract (BE) and 
Ethanol extract (EE) of the roots of Pongamia pinnata L., showed significant 
analgesic effect in the tail flick test. The PEE and EE of the seeds also showed 
significant analgesic activity at doses higher than 100 mg/ kg
29
. 
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 Srinivasan et al., 2001 evaluated the anti-inflammatory activity of ethanolic extract 
of Pongamia pinnata L., leaves (PPLE) in acute, subacute and chronic models of 
inflammation was assessed in rats. Oral administration of PPLE (300, 1000 mg/kg) 
exhibited significant anti-inflammatory activity in acute (carrageenin, histamine, 5-
hydroxytryptamine and prostaglandin E2-induced hind paw edema), subcute (kaolin-
carrageenin and formaldehyde-induced hind paw edema) and chronic (cotton pellet 
granuloma) models of inflammation. PLE did not show any sign of toxicity and 
mortality up to a dose level of 10.125 g/kg, p.o in mice. Both acute as well as chronic 
administration of PLE (100, 300 and 1000 mg/kg, p.o) did not produce any gastric 
lesion in rats. These results indicate that PLE possesses significant anti-inflammatory 
activity without ulcerogenic activity suggesting its potential as an anti-inflammatory 
agent for use in the treatment of various inflammatory diseases
30
. 
 
 Simonsen et al., 2001 in their study have reported that the Pongamia pinnata L., 
shows anti-plasmodial activity against Plasmodium falcipar
31
. 
 
 The antibacterial activity of various extracts of Pongamia pinnata L., seeds was 
evaluated by Dayanand et al., 2013. The methanol extracts of Pongamia pinnata L., 
L (PPM) showed higher antibacterial activity than ethanol extracts of Pongamia 
pinnata L., (PPE). Pongamia pinnata L., L has good bactericidal activity against the 
selected Hospitalized pathogens and the maximum activity was evinced on 
Pseudomonas aeruginosa, with a zone of inhibition 20mm by methanol extract and 
18.5mm on Pseudomonas aeruginosa in ethanol extract in comparison to 
Ceftazidime
32
. 
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 Singh R K et al., 1997 have reported that the petroleum ether extract (PEE) of the 
roots enhanced pentobarbitone sleeping time, probably due to CNS depression. The 
PEE of the seed of Pongomia pinnata L., was further tested for nootropic activity in 
an experimental model of Alzheimer’s disease (created by ibotenic acid induced 
lesioning of nuclear basali magnocellularis). It reversed both the cognitive deficits and 
the reduction in cholinergic markers after 2 weeks of treatment. Reversal of perturbed 
cholinergic function was considered as the possible mechanism
33
. 
 
2.2. PHYTOCHEMICAL STUDIES 
 
 Prashanth G.K et al., 2014 have reported the phytochemical screening of the 
aqueous and ethanolic extracts of the leaves of Pongamia pinnata L., revealed the 
presence of alkaloids, carbohydrates, reducing sugars etc. GC-MS analysis of the 
ethanolic extract indicated the presence of many constituents in the leaves of 
Pongamia pinnata L., such as Alkaloids, Glycoside, Saponins, Tannins and phenolic 
compounds
34
. 
 
 Vismaya et al., 2010 have reported the Karanja (Pongamia pinnata L.,) seed oil 
contains karanjin, a bioactive molecule with important biological attributes. They 
subjected the seed oil to liquid–liquid extraction with methanol. The extract was 
further purified by chromatography on alumina followed by crystallization to afford 
karanjin, whose purity was ascertained by HPLC. They obtained the recovery of 
karanjin as 20% with >95% purity. The structure of the compound was elucidated by 
MS and NMR spectral analysis
35
. 
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 Isolation and characterization of five structurally unusual flavonoids pongamones A–
E, along with 16 known flavonoid metabolites were carried out by from the stem of 
Pongamia pinnata L., by Li et al 2006. Their structures were determined on the basis 
of spectroscopic analyses and by comparison of their spectroscopic data with those of 
related compounds reported in the literature
36
. 
 
 Yadav et al., 2004 isolated four new furanoflavonoids, pongapinnol A–D and a new 
coumestan, pongacoumestan along with thirteen known compounds from the fruits of 
Pongamia pinnata L., They elucidated the structures of isolated compounds on the 
basis of spectroscopic data interpretation
37
. 
 
 Kalidhar et al., 2003 investigated the chemical constituents of the roots of Pongamia 
pinnata L., Four compounds, karanjin, pongachromene, pongapin and 
demethoxykanugin were characterized from the methanolic extract of the roots
38
. 
 
 Six compounds (two sterols, three sterol derivatives and one disaccharide) together 
with eight fatty acids (three saturated and five unsaturated) have been isolated from 
the seeds of Pongamia pinnata L., by Shameel S et al., 1996. The metabolites, beta-
sitosteryl acetate and galactoside, stigma sterol, its galactoside and sucrose are being 
reported from this plant. The saturated and unsaturated fatty acids (two monoenoic, 
one dienoic and two trienoic) were present in exactly the same amount. Oleic acid 
occurred in highest amount (44.24%), stearic (29.64%) and palmitic (18.58%). 
Hiragonic and octadecatrienoic acids were present in trace amounts (0.88%). 
Karangin, pongamol, pongagalabrone and pongapin, pinnatin and kanjone have been 
isolated and characterized from seeds. Immature seeds contain a flavone derivative 
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pongol. The other flavonoid isolated from the seeds includes glybanchalcone, 
isopongachromene
39
. 
 
2.3. LIST OF REVIEW ON THE MODELS USED FOR HEPATOPROTECTIVE 
EVALUATION 
            
           Various models used to investigate the heptoprotective activity are, 
 
 CCl4 induced hepatotoxicity
40 
 Ethanol induced hepatotoxicity41 
 Paracetamol induced hepatotoxicity15 
 Lead acetate induced hepatotoxicity42 
 
         CCl4 induced hepatotoxicity is one of most commonly used models for the evaluation 
hepatoprotective activity. The hepatoprotective activity of various plants was carried out by 
utilising CCl4 model as an inducing method. Some of the plants that have been evaluated for 
hepatoprotecive activity using CCl4 model are Viburnum punctatum
43
, Eurycoma longifolia
44
, 
Vitis vinifera
45
, Cissampelos pareira
46
, Prunnus domestica
47
, Parmelia perlata
48
, Mallotus 
mull-Arg
49
, Mimosa pudica
50
, Solanum trilobatum
51
. 
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3. PLANT PROFILE 
Pongamia  pinnata (Linn.,) belongs to the family Papilionaceae.  
SYNONYMS 
Derris indica(Lam.,)Bennett. 
Millettia novo - guineensis Kane.  
Pongamia glabra Vent. 
Pongamia  pinnata  Merr  
BOTANICAL CLASSIFICATION 
Kingdom : Plantae 
Subkingdom : Tracheobionta 
Superdivision : Spermatophyta 
Division : Magnoliophyta  
Class : Magnoliopsida 
Subclass : Rosidae 
Order : Fabales 
Family : Leguminoseae 
Genus : Pongamia 
Species : Pinnata 
BOTANICAL NAME 
          Pongamia pinnata (L.,) pierre 
VERNACULAR NAMES
52 
Hindi, Beng., Mar. and Guj :  Karanj, Karanja 
Sanskrit                                :   Naktamala 
English                                 :  Indian beech 
Telugu                                  :   Pungu, Gaanuga 
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Tamil                                   :  Ponga, Pongam 
Malayalam                           :   Pungu, Punnu 
Oriza                                    :  Koranjo 
Punjab                                  :   Sukhehein, Karanj, Paphri 
Assam                                  :  Karchuw 
 
Figure. 4 
       
                                 
                         A                                                                              B 
                                                                   
                                
                        C                                                                               D 
Figure A :   Pongamia pinnata L., whole plant 
Figure B :   Leaves 
Figure C :   Flower 
Figure D :   Seeds 
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GEOGRAPHICAL DISTRIBUTION 
                   It is widely distributed throughout tropical Asia and the Seychelles Islands, South 
Eastern Asia, Australia, India and locally distributed throughout the State of Maharashtra 
(India) along the banks of rivers, very common near the sea-coast in tidal and beach-forests in 
Konkan along Deccan rivers
53
. 
 
BOTANICAL DESCRIPTION  
Plant type 
Medium           -   sized, evergreen, perennial and deciduous tree 
Height             -   35 to 40 feet 
Growth rate     -   Fast 
Texure             -   Medium 
Growing requirements 
Light requirement - Tree grows in full sun. 
Soil tolerance        - Clay, loam, sandy, slightly alkaline, acidic, well-drained. 
Macroscopy 
 Leaf          -   Alternate, odd pinnately compound, evergreen, hairless.  
 Flower      -    Lavender, pink; white, 2- 4 together, short-stalked, pea shaped, 15-18mm           
                       long. 
Pods           -    3-6cm long and 2-3cm wide, smooth, brown, thick-walled, hard, indehiscent. 
Seed           -    Compressed ovoid or elliptical, bean-like, 10-15cm long, dark brown, oily.  
Root          -    Tap root is thick and long, lateral roots are numerous and well developed. 
Bark          -   Thin gray to grayish brown and yellow on the inside. 
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PHYTOCHEMICAL CONSTITUENTS 
 Phytochemical investigation of Pongamia pinnata L., indicated the presence of 
abundant prenylated flavonoids such as furanoflavones, furanoflavonols, chromenoflavones, 
furanochalcones and pyranochalcones. 
 Karanja (Pongamia pinnata L.,) seed oil contains karanjin a bioactive molecule with 
important biological attributes. 
 Pongamia pinnata L., contain 30 to 40% pongam oil and also called pongomol or 
Hongay oil. 
 The total saturated and unsaturated fatty acid composition was 20.5% and 79.4% 
respectively.  The major mono unsaturated fatty acid was oleic acid 46% whereas linoleic 
acid 27.1% and Linolenic acid 6.3% constitutes the total polyunsaturated fatty acid. Low 
molecular weight fatty acids such as lauric and capric acids occure in very small amount of 
about 0.1% each. 
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Table - 1 
ECONOMIC AND MEDICINAL IMPORTANCE OF PONGAMIA PINNATA (L.,) 
53,54
 
  
Economic 
value 
Used as cattle fodder. 
Used in stored grains to repel insects. 
Used as manure for rice and sugarcane fields 
 
Leaf 
 
 
Medicinal 
value 
Juice of leaves is used for cold, cough, diarrhea, dyspepsia, 
flatulence, gonorrhea, leprosy. 
Leaves are antihelminthitic, digestive and laxative used for 
inflammations, piles, hepatoprotective and wounds. 
As an infusion to relieve rheumatism. 
As an extract to treat itches and herpes. 
 
 
Flower 
 
Economic 
value 
Good source of pollen for honey bees. 
Flowers are edible. 
 
Medicinal 
value 
Useful to quench dipsia in diabetes for alleviating vata 
kapha and for bleeding piles 
 
 
 
 
Root 
 
Economic 
value 
 
Root is used as fish poison 
 
 
Medicinal 
value 
Juice of roots with coconut milk and lime water used for 
treatment of gonorrhea. 
Used for cleaning gums, teeth and ulcers. 
Roots are bitter anti-helmintic and used in vaginal and skin 
diseases. 
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Juice of the root is used for cleansing foul ulcers and 
closing fistulous sores. 
 
 
 
Fruit 
 
 
 
 
 
 
 
Seed 
Economic 
value 
Fruits are edible 
 
Medicinal 
value 
Fruits used for abdominal tumors. 
Useful in ailments of female genital tract, leprosy, tumour, 
piles, ulcers 
and upward moving of the wind in the abdomen. 
 
Economic 
value 
After oil extraction the marc has been used as “green 
manure” as it is rich in protein and nitrogen. 
Used as insecticides. 
 
Medicinal 
value 
Used for keloid tumors. 
Used in hypertension, skin ailments and rheumatic arthritis. 
Seed powder valued as a febrifuge, tonic and in bronchitis 
and whooping cough. 
Useful in inflammations, pectoral diseases, chronic fevers, 
hemorrhoids and anemia. 
 
 
Stem 
Economic 
value 
Used for stove top fules. Used as poles and carving 
Ash of wood used for drying 
Agriculture implements, tool handles and combs. 
Medicinal 
value 
Aqueous extracts of stem bark exhibit significant CNS  
sedative and antipyretic activity. 
 
 
 
 
Economic 
value 
Used as fuel for cooking and lamps, as a lubricant, water-
paint binder, pesticide and in soap-making, candles and 
tanning industries. 
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Oil 
Used as lipids for commercial processes. 
Used in cosmetics. 
Medicinal 
value 
Oil is styptic, anthelmintic and useful in leprosy, piles, 
ulcers, chronic fever and in liver pain. 
Useful in rheumatism arthritis, scabies, whooping cough. 
Mixture of oil and zinc oxide used for eczema. 
 
 
Bark 
Economic 
value 
String and rope can be made from the bark fiber. 
Used for paper pulp 
Medicinal 
value 
For bleeding piles, for beriberi, reduces swelling of the 
spleen. 
Useful in mental disorder, cough and cold. 
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4. AIM AND OBJECTIVE 
 
From the literature review it has been found that 
 Pongamia pinnata L., has been reported to possess antioxidant activity and 
antioxidants are known to be associated with hepatoprotective activity. Plants 
containing flavonoids are known to exihibit the hepatoprotective activity. 
 In this plant, the leaves and stem bark of Pongamia pinnata L., have been shown to 
possess hepatoprotective activity. No work has so far been carried out on the seeds of 
Pongamia pinnata L., 
 
Hence, the aim and objective of the present study is  
 To evaluate the in vitro hepatoprotective activity of the seeds of Pongamia pinnata L., 
by MTT assay using normal Chang liver cell line. 
 To evaluate the in vivo hepatoprotective activity of the seeds of Pongamia pinnata L., 
by using Carbon tetrachloride induced hepatotoxicity model in Wistar rats.   
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5. PLAN OF WORK  
                                     
 
 
 
 
 
Collection of seeds 
      Authentication of plant material  
Processing and extraction of seeds with 90% ethanol 
Pharmacological studies 
In vivo study 
(CCl4 model) 
                     In vitro studies 
MTT (Microculture Tetrazolium Test) 
assay by using Chang liver cell lines 
Evaluation of 
antioxidant enzymes 
Evaluation of bio 
chemical parameters 
Histopathological 
studies 
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6. MATERIALS AND METHODS 
 
6.1. Plant collection and identification
55-57
 
             Dried seeds of Pongamia pinnata L., were collected from the forest around Kutralam 
hills, Tirunelveli District, Tamilnadu (India) in the month of August 2015. The plant was 
authenticated by Prof. V. Chelladurai, Research Officer- Botany (Scientist - C) (Retd), 
Central Council for Research in Ayurveda & Siddha, Govt. of India. 
 
6.2. Preparation of plant extract 
          The freshly collected seeds of this plant was chopped, shade dried. The dried material 
was powdered and passed through a 10-mesh sieve. The powder was then extracted with 
ethanol (90%) using a Soxhlet extractor. In this process, the vapour from the solvent is 
carried to the condenser, where it condenses liquid returns to the flask for continuous 
extraction. 
Procedure 
 50g of dried powdered seeds was weighed and transferred into thimble of the Soxhlet 
apparatus for packing. 
 While packing, the content was wetted with 90% ethanol (the solvent used) and then 
poured until the siphon tube was filled. 
 A piece of porcelain was added into the round bottom flask to avoid bumping effect. 
 
          The extracts were concentrated by using a rotary evaporator. The extract was then 
subjected to in vitro and in vivo hepatoprotective evaluation. 
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6.3. IN VITRO STUDIES 
6.3.1. IN VITRO HEPATOPROTECTIVE ACTIVITY BY MTT ASSAY USING 
CHANG LIVER CELL LINE
58
 
The ethanolic extract of seeds of Pongamia pinnata L., was subjected to evaluation of in vitro 
hepatoprotective activity. 
Reagents 
 MEM (Minimal Essential Media) purchased from Hi Media Laboratories, Mumbai 
 FBS (Fetal Bovine Serum) purchased from Cistron laboratories 
 Trypsin, MTT [3-(4, 5- Dimethyl thiazol -2-yl) - 5- diphenyl tetrazolium bromide] 
was purchased from Sisco Research Laboratory Chemicals, Mumbai. 
 DMSO (Dimethyl sulfoxide) was purchased from Sisco Research Laboratory 
Chemicals, Mumbai. 
Cell line and culture 
 Normal Chang liver cell lines were obtained from National Centre for Cell Sciences 
(NCCS), Pune. The cells were maintained in Minimal Essential Medium 
supplemented with 10% FBS, Penicillin (100 U/ml) and Streptomycin (100 μg/ml) in 
a humidified atmosphere at 37ºC. 
 Maintenance of cultures was passaged weekly and the culture medium was changed 
twice a week. 
MTT ASSAY 
Principle 
MTT assay is a standard colorimetric assay used for measuring the viability of cells. It 
can be used indirectly to evaluate the cytotoxicity of the sample under study. 
The assay is based on conversion of the MTT [3-(4, 5 – dimethyl thiozol – 2-yl)-2, 5- 
diphenyl tetrazolium bromide], a yellow tetrazole to a purple coloured formazan crystal by 
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the active mitochondrial reductase (or cellular reductase) present in the viable cells. The 
colour solution can be quantified by measuring absorbance, the purple colour thus formed is 
directly proportional to the number of viable cells present. 
Procedure 
Cytotoxicity evaluation by tetrazolium (MTT) assay 
 The Chang liver monolayer cells were detached with Trypsin-ethylene diamine tetra 
acetic acid (EDTA) to make single cell suspension and the viable cells were counted 
using a haemocytometer and diluted with medium along with 5% Fetal Bovine Serum 
(FBS) to give final density of 1×10
5
 cells/ml. 
 Cells (1×105 cells/ml) were plated in 5ml of medium/well in 96 well plates (Coster 
Coring, Rochester, NY). 
 After 48 hours incubation, the cell reaches the confluence.  
 Then, cells were incubated with different concentrations of Silymarin, EPPS for 24 
hours at 37ºC. 
 After removal of the sample solution and washing with phosphate-buffered saline (pH 
7.4), 200µl of (5mg/ml) of 3-(4, 5 – dimethyl thiozol - 2-yl)-2, 5- diphenyl 
tetrazolium bromide cells (MTT) phosphate-buffered saline solution was added each 
well. 
 After 4 hour incubation, 0.04M HCl/isopropanol were added. 
 Viability of cells was determined by measuring the absorbance at 570nm using UV 
spectrophotometer and wells not containing sample were treated as blank. 
 Measurements were performed and the concentration required for a 50% inhibition of 
viability (IC50) was determined graphically. 
 Triplicate was maintained for all concentrations. 
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 The effect of the samples on the proliferation of Chang Liver cells was expressed as 
the % cell viability, using the formula 
              OD of treated cells 
% cell viability =                                             × 100 
              OD of control cells 
6.3.1.2. IN VITRO HEPATOPROTECTIVE ACTIVITY OF SILYMARIN AND EEPPS 
AGAINST CCl4 INDUCED TOXICITY BY MTT ASSAY USING CHANG LIVER 
CELL LINE 
 Since the extract was found to be as safe Silymarin and the CTC50 value of both 
EEPPS, Silymarin were approximately 100µg/ml, the hepatoprotective activity was 
determined at various concentration with a maximum of 100 µg/ml. 
Reagents 
 MEM (Minimal Essential Media) purchased from Hi Media Laboratories, Mumbai 
 FBS (Fetal Bovine Serum) purchased from Cistron laboratories 
 Trypsin, MTT [3-(4, 5- Dimethyl thiazol -2-yl) - 5- diphenyl tetrazolium bromide] 
was purchased from Sisco Research Laboratory Chemicals, Mumbai. 
 DMSO (Dimethyl sulfoxide) was purchased from Sisco Research Laboratory 
Chemicals, Mumbai. 
Cell line and culture 
 Normal Chang liver cell lines were obtained from National Centre for Cell Sciences 
(NCCS), Pune. The cells were maintained in Minimal Essential Medium 
supplemented with 10% FBS, Penicillin (100 U/ml) and Streptomycin (100 μg/ml) in 
a humidified atmosphere at 37ºC.Maintenance of cultures was passaged weekly and 
the culture medium was changed twice a week. 
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MTT ASSAY 
Principle 
        MTT assay is a standard colorimetric assay used for measuring the viability of cells. It 
can be used indirectly to evaluate the cytotoxicity of the sample under study. 
        The assay is based on conversion of the MTT [3-(4, 5 – dimethyl thiozol - 2-yl)-2, 5- 
diphenyl tetrazolium bromide], a yellow tetrazole to a purple coloured formazan crystal by 
the active mitochondrial reductase (or cellular reductase) present in the viable cells. The 
colour solution can be quantified by measuring absorbance, the purple colour thus formed is 
directly proportional to the number of viable cells present. 
Procedure 
The Chang liver monolayer cells were detached with trypsin-ethylene diamine tetra-acetic 
acid (EDTA) to make single cell suspensions and viable cells were counted using 
Haemocytometer and diluted with medium along with 5% FBS to give final density of 1×10
5 
cells/ml. 
 Cells (1×105/well) were plated in 5ml of medium/well in 96 well plates (Coster 
Coring, Rochester, NY). 
 After 48 hours incubation, the cell reaches the confluence. 
 Then, cells were challenged with Hepatotoxicant (CCl4) 125µg/ml and different 
concentration (100, 50, 25, 10µg/ml) of extract and the Standard drug (Silymarin) 
were added. The cells were incubated for 24-48 hours at 37ºC. 
 After removal of the sample solution and washing with phosphate-buffered saline (pH 
7.4), 200µl of (5mg/ml) of 3- (4, 5 - dimethyl thiozol -2-yl)-2, 5- diphenyl tetrazolium 
bromide cells (MTT) phosphate-buffered saline solution was added each well. 
 After 4 hour incubation, 0.04M HCl/isopropanol were added. 
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 Viability of cells was determined by measuring the absorbance at 570nm using UV 
spectrophotometer and wells not containing sample were treated as blank. 
 Measurements were performed and the concentration required for a 50% inhibition of 
viability (IC50) was determined graphically. 
 Triplicate was maintained for all concentrations. 
 The effect of the samples on the proliferation of Chang Liver cells was expressed as 
the % cell viability, using the formula 
  OD of treated cells 
% cell viability = × 100 
                      OD of control cells 
6.4. IN VIVO STUDIES
 
Experimental Animals 
         The present study was conducted after obtaining approval from the Insitutional Animal 
Ethics Committee, Madras Medical College, Chennai-03 and this protocol met the 
requirements of national guidelines of CPCSEA (PROPOSAL NO: 03/243/CPCSEA) The 
Wistar rats (150-200g) used for this study were procured from, Insitutional Animal Ethics 
Committee, Madras Medical College, Chennai-03, India. 
Quarantine and Acclimatization 
          Quarantine is the separation of newly received animals from those already in the 
facility until the health and possibly the microbial status of the newly received animals have 
been determined. The newly procured Wistar albino rats were quarantined for the period of 
one week to minimize the chance of introduction of pathogens into established animals and 
allowed to develop the physiological and nutritional stabilisation before their use. 
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Housing 
       The animals were housed in well ventilated animal house which was maintained at a 
constant temperature and relative humidity of 55 – 65%. The animals were housed in 
spacious polypropylene cages and paddy husk was utilized as bedding material. 
Diet and water 
       The animals were maintained on standard pellet diet and purified water. The animals 
were provided with food and water ad libitum expect during fasting. The bedding material 
was changed frequently. 
Drug administration   
        Drug was administered by oral gavage using oral feeding tube fixed to a syringe needle 
to administer the required quantity of the drug. 
Animal identification 
        All animal cages used in the study had a proper identification i.e. labels. Each animal in 
the cage was marked either on head or body or tail with picric acid for their appropriate 
identification. 
6.4.1. IN VIVO HEPATPROTECTIVE EVALUATION OF EEPPS WITH CCl4 
MODEL OF HEPATOTOXICITY
41,46,59 
        The ethanolic extract of seeds of Pongamia pinnata L., was subjected to evaluation of in 
vivo hepatoprotective activity. 
Drugs and chemicals 
 Carbon tetrachloride 
 Silymarin 
 β - cyclo dextrin (BCD) 
Preparation of drug solutions 
            Carbon tetrachloride was dissolved in olive oil 1:1 
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            Ethanol extract was dissolved in 1% BCD 
            Standard drug (Silymarin) was dissolved in distilled water. 
Experimental method 
           Carbon tetrachloride induced hepatotoxicity in wistar albino rats was used as a model 
for screening for hepatoprotective activity. 
6.4.1.1. Acute toxicity study 
           Acute toxicity studies have been already done and it was found to be safe upto 
2000mg/kg p.o. Hence, the doses selected for this study were 200mg/kg and 400mg/kg p.o.
23 
                                                                    
HEPATOPROTECTIVE EVALUATION 
Rats were divided into five groups consisting of 6 animals each. 
GROUP 1     :  Received a single oral dose of BCD (1ml of 1%, w/v)  
GROUP 2     : The animals were injected a mixture of carbon tetrachloride in olive oil in a    
                      dose of 1ml/kg body weight, i.p, once every 72 hours for 14 days and       
                      received daily a single oral dose of BCD (1ml of 1%, w/v)    
GROUP 3     : The animals received daily oral dose of standard drug Silymarin 25mg/kg for   
                      14 days. The mixture of carbon tetrachloride in olive oil (1ml/kg body  
                      weight, i.p, once every 72 hours for 14 days and       
                      received daily a single oral dose of BCD (1ml of 1%, w/v)    
GROUP 4     : The animals received daily oral dose of 200mg/kg body weight of ethanolic   
                      extract of Pongamia pinnata L., seeds (EEPPS) in BCD. 
GROUP 5     : The animals received daily oral dose of 400mg/kg body weight of ethanolic   
                      extract of Pongamia pinnata L., seeds (EEPPS) in BCD.
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S. 
NO 
 
GROUP 
(n=6) 
 
TREATMENT 
 
TREATMENT SCHEDULE 
 
 
1 
 
I 
                    
Normal control 
 
 
1ml of 1% BCD p.o for 14 days  
 
2 
 
II 
 
Disease control 
1ml/kg CCl4 in olive oil (1:1), i.p, once in every 72h for 14 
days 
 
 
3 
 
 
III 
 
Standard control 
 
1ml/kg CCl4 in olive oil (1:1), i.p, once every 72 h for 14 days  
+ 
      25mg/kg  p.o of Silymarin, daily for 14 days 
 
4 
 
IV 
 
Test group I 
1ml/kg CCl4 in olive oil (1:1), i.p, once every 72 h for 14 days  
+ 
200mg/kg of EEPPS p.o, daily for 14 days 
 
5 
 
V 
 
Test group II 
1ml/kg CCl4 in  olive oil (1:1), i.p, once every 72h for 14 days  
+ 
400mg/kg EEPPS p.o, daily for 14 days 
 
          For all rats, body weight was measured before and after the induction of hepatotoxicity 
(1
st 
and 15
th
 day). On the 15
th
 day, blood samples were collected by retro orbital puncture for 
estimation of biochemical parameters. The animals were sacrificed by cervical dislocation 
method. The liver was removed rinced in ice cold saline and stored in 10% formalin solution. 
A part of liver was homogenised with Phosphate buffer, pH 7.4 using a Teflon homogenizer 
in ice-cold condition. The homogenate was centrifuged at 5000 rpm for 10min. The 
supernatants solution was taken up for the evaluation of Lipid peroxidation (LPO), 
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Superoxide dismutase (SOD) levels. The other part of liver was subjected to 
histopathological study. 
 
6. 5. BIOCHEMICAL PARAMETERS 
            The blood samples were collected and allowed to clot and centrifuged at 2000 rpm for 
15-20 minutes using REMI (412 LAG) cooling centrifuge. The serum      ept - 0 C until 
analysed. Levels of Total protein, Albumin, Total Bilirubin, Alanine aminotransferase (ALT), 
Aspartate aminotransferase (AST), Serum alkaline phosphatase (ALP) were determined with 
an Automated Analyser (Hitachi 911, Japan). 
 
6.5.1. Estimation of Aspartate Aminotransferase
60
 (AST/SGOT) 
               Aspartate aminotransferase (AST) also referred to as Serum glutamate oxaloacetate 
transferase (SGOT), is an enzyme involved in amino acids metabolism. AST is widely 
distributed in liver, RBC, heart, pancreas and kidney. A high level of AST in blood is 
observed in severe liver disease, kidney disease and lung disease. 
Principle  
    - Ketoglutarate + L – Aspartate   SGOT    L –Glutamate + Oxaloacetate 
  Oxaloacetate + NADH + H
+
              MDH       L – Malate + NAD+ 
         The rate of NADH consumption is measured photometrically and is directly 
proportional to the AST concentration in the sample. 
Reagents 
 L – Aspartate 200mmol/l 
 Malate dehydrogenase 200mmol/l 
   - Ketoglutarate 35mmol/l 
 NaOH 1.05mmol/l 
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Procedure 
          800µl of L - Aspartate & Malate dehydrogenase and 200µl of    - Ketoglutarate are 
mixed together and incubated at 37ºC for 2 minutes and 100 µl of sample is added. The 
change in absorbance is measured at 340nm. 
Calculation 
               AST = Abs/ min × 1764(Factor) 
 
6.5.2. Estimation of Alanine Aminotransferase
61 
(ALT/SGPT) 
              Alanine aminotransferase/ Serum Glutamate Pyruvate Transferase is an enzyme 
which is involved in amino acids metabolism.  
Principle 
     - Ketoglutarate + L – Alanine   SGPT   L – Glutamate + Pyruvate 
   Pyruvate + NADH + H
+                    
   LDH     L – Lactate + NAD+ 
            The rate of NADH consumption is measured photometrically and is directly 
proportional to the SGPT concentration in the sample. 
Reagents     
 L – Alanine 200mmol/l 
 Lactate Dehydrogenase 1500mmol/l 
   - Ketoglutarate 35mmol/l 
 NADH 1.05mmol/l 
 Tris buffer 80mmol/l pH 7.5 
Procedure 
            800µl of L – Alanine and Lactate dehydrogenase and 200µl of   - Ketoglutarate are 
mixed together and incubated at 37ºC for 2minutes and 100µl of sample is added. The change 
in absorbance is measured at 340nm. 
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Calculation 
      ALT =  Abs/min × 1764(Factor) 
6.5.3. Estimation of Alkaline Phosphatase (ALP) 
Principle 
        When the enzymes incubated with p-nitro phenyl phosphate and Tris buffer (pH 9.6) in 
alkaline condition inorganic phosphate and p-nitro phenol are formed by the catalytic action 
of alkaline phosphatase. Amount of p-nitro phenol liberated by the enzyme is measured at 
420nm. 
2-amino-methyl-1-propanol+p-nitro phenyl phosphate + H2O 
 
 
4-nitro phenol+ 2-amino-2-methyl-1-propanol phosphate 
 
Requirements 
 P-nitro phenyl phosphate (10mM) 
 Tris-HCl pH 9.6 (80mM) 
 NaOH (0.1N) 
Procedure 
           1ml of p-nitro phenyl phosphate and 1.5ml of buffer were added with 100µl of 
homogenate. The mixture was incubated at 37ºC for 30mins. Then the reaction was stopped 
by addition of 0.1 N NaOH. The absorbance of liberated p-nitro phenol was measured at 
420nm. 
Calculation 
ALP U/I = ∆A/ 2764 
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6.5.4. Estimation of Total Bilirubin (TB) 
Principle 
   Method of Malloy and Evelyn used to estimate serum bilirubin level. 
   Direct   : (Conjucated) Bilirubin couples with diazotized  Sulfanilic acid, forming   
                   Azobilirubin, a red-purple coloured product in acidic medium. 
   Indirect : (Unconjucated) Bilirubin is diazotized only in the presence of its dissolving  
                   solvent (Methanol). Indirect fraction and thus represents Total bilirubin                      
                   concentration. The difference of Total and Direct Bilirubin gives Indirect                   
                   (Unconjucated) Bilirubin. 
          The intensity of red-purple colour so developed above is measured calorimetrically and 
it id proportional to the concentration of the appropriate fraction of Bilirubin. This reaction 
can be represented as:          
                                                                          H
+ 
Bilirubin + Diazotized Sulfanilic Acid                            Azobilirubin 
                                                                                                   
                                                                        Red-purple colour (λ max 540nm) 
 
 
Reagents 
        Diazo-A, Diazo-B and Diazo blank 
        Methanol 
        Artificial standard (100mg bilirubin)            
        Diazo reagent: Just before use, mix 1.0ml of Diazo-A with 0.030ml of Diazo-B 
 
 
 
Materials and Methods 
 
Institute Of Pharmacology, MMC Page 44 
 
Procedure 
0.1ml of serum, 0.25 ml of diazo reagent and methanol 1.25ml were mixed well and kept in 
dark at room temperature for 30mins and read the optical density (O.D) at 540nm against 
distilled water on a colorimeter with a yellow green filter. 
Calculation 
 O.D.T1 – O.D.T2  
 Total Bilirubin =  × 10 
 O.D. Standard  
 
6.5.5. Estimation of Total Protein (TP)
 62 
(Biuret Method) 
            The serum content of the soluble proteins, those circulating in extracellular and 
intracellular fluids, has been used as a marker to aid in clinical diagnosis. Serum total protein 
including albumin is mainly involved in the maintenance of osmotic pressure of plasma and 
is used to transport many substances including macromolecules. 
Principle 
           In the biuret reaction, a chelate is formed between the Cu
2+
 ion and the peptide bonds 
of the proteins in alkaline solutions to form a violet coloured complex whose absorbance is 
measured photometrically at 540nm. The intensity of the colour produced is proportional to 
the concentration of the protein in the sample. 
 
               Cu
2+
 + Serum protein  Copper-protein complex  
                                                                          (Violet coloured) 
Reagents 
 Total protein reagent (Biuret reagent) 
 Protein standard (Standard prepared from bovine serum albumin)  
 Serum sample from animals 
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Procedure 
         1ml of biuret reagent which is stored under 2-8ºC and 10µl of serum sample/standard 
are mixed well and incubated for 5mins. The intensity of the colour is measured at 540nm. 
 
Calculation 
 Absorbance of test 
 Total protein in gm/ml = 
 Absorbance of standard 
 
 
6.5.6 Estimation of Albumin (ALB) 
Principle 
Bromocresol-Green (BCG) method 
         When albumin binds with bromocresol green in a suitable buffer, pH 4.15-4.25, an 
intense blue coloured albumin-BCG complex is formed  
     Albumin + BCG (Yellow)                Albumin-BCG complex (blue) 
Reagents 
        Bromocresol green reagent 
        Serum sample from animals 
Procedure 
        1ml of bromocresol reagent, 1.5ml of buffer and 0.2ml serum were mixed and kept at 
room temperature for 10mins. The absorbance was measured at 630nm. 
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6.6 ESTIMATION OF LIPID PEROXIDATION AND SUPEROXIDE DISMUTASE 
LEVELS 
6.6.1. Estimation of Lipid Peroxidation (LPO)
 63 
The extent of lipid peroxidation was estimated as evidenced by the formation of 
Thiobarbituric acid reactive substance (TBARS). The pink colored chromogen formed by the 
reaction of 2-thiobarbituric acid (TBA) with breakdown products of lipid peroxidation was 
read at 532 nm.  
Reagents 
1. 8.1% sodium dodecyl sulphate (SDS) 
2. 20 % v/v acetic acid. 
3. 0.5% v/v TBA 
4. n-butanol and pyridine (15:1 v/v) 
5. Stock malondialdehyde solution 
  1,1,3,3 - tetramethoxy propone (184 µg/ml) 
Procedure 
To 0.2 ml of liver tissue homogenate, 0.2 ml of 8.1 % SDS, 1.5 ml of 20 % acetic 
acid, solution (adjusted to pH 2 to 3.5 with NaOH) and 1.5 ml of 0.8 % aqueous solution of 
TBA were added. The mixture was made up to 4.0 ml with distilled water and then heated in 
a water bath at 95°C for 60 minutes. After cooling with tap water, 1.0 ml of distilled water 
and 5.0 ml of a mixture of n-butanol and pyridine were added and shaken vigorously. After 
centrifugation at 4000 g for 10 minutes, the organic layer was removed and its absorbance at 
532nm was measured. 
Values were expressed as n moles/100 mg protein. 
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6.6.2. Estimation of Superoxide Dismutase (SOD) 
64 
                   The assay is based on the inhibition of the formation of  
NADH-phenazine methosulphate-nitroblue tetrazolium formazon. The reaction was initiated 
by the addition of NADH. After incubation for 90 sec, addition of glacial acetic acid stops the 
reaction. The colour developed at the end of the reaction was extracted into n-butanol layer 
and measured in a spectrophotometer at 520 nm.  
Reagents  
1. Sodium pyrophosphate buffer: 0.025 M, pH. 8.3 
2. Absolute ethanol 
3. Chloroform 
4. n-butanol 
5. Phenazine methosulphate (PMS): 186 mol 
6. Nitroblue tetrazolium (NBT)      : 300 mol 
7. NADH                                        : 780 mol 
Procedure  
 0.5 ml of tissue homogenate was diluted to 1.0 ml with water followed by addition of 
2.5 ml of ethanol and 1.5 ml of chloroform (chilled reagents were added). This mixture was 
shaken for 90 sec at 4 C and then centrifuged. The enzyme activity in the supernatant was 
determined as follows. The assay mixture contained 1.2 ml of sodium pyrophosphate buffer, 
0.1 ml of phenazine methosulphate and 0.3 ml of nitroblue tetrazolium and appropriately 
diluted enzyme preparation in a total volume of 3 ml. The reaction was started by the addition 
of 0.2 ml NADH. After incubation at 30 C for 90 sec, the reaction was stopped by the 
addition of 1 ml glacial acetic acid.  The reaction mixture was stirred vigorously and shaken 
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with 4 ml n-butanol. The mixture was allowed to stand for 10 min, centrifuged and n-butanol 
layer was separated. The colour density of the chromogen in n-butanol was measured at 510 
nm. A system devoid of enzyme served as control. The enzyme concentration required to 
inhibit the chromogen produced by 50% in one minute under standard conditions was taken 
as one unit.  
SOD activity was expressed as Unit/min/mg of protein  
6.7. HISTOPATHOLOGICAL STUDIES
65
 
             The liver from the animals was rinsed in ice cold 0.9% saline and was fixed in 10% 
formalin embedded in paraffin and cut into 5µm thick section using a microtome. Sections 
were mounted on glass slides using standard techniques. The sections were stained with 
Haematoxylin - Eosin and were examined under a microscope using 100 x magnifications 
and photographed under a light microscope equipped for photography (Olympus CK 40). 
STATISTICAL ANALYSIS 
             All the values were expressed as mean ± SD. The data was statistically analysed by 
one   y ANOVA follo ed by Dunnet’  te t. One   y  n ly i  of v ri nce (ANOVA)     
used to correlate the statistical difference between the variables. P<0.05 was considered to be 
significant.  
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7. RESULTS 
  
6.3. IN VITRO STUDIES 
 The ethanolic extract of Pongamia pinnta L., seed was prepared by Soxhlet 
extraction. The extract was greenish brown in colour and it was semi solid in nature. 
6.3.1. Cytotoxicity evaluation by MTT assay 
 The cytotoxicity studies were carried out for the standard drug Silymarin and 
ethanolic extract of Pongamia pinnata L., seeds (EEPPS) on the Chang liver cell line using 
different concentration range (50, 100, 200, 300,400, 500µg/ml) and its CTC50 values was 
determined. (Table 2and Figure. 5) 
Table - 2 
MTT assay of Silymarin and ethanolic extract of Pongamia pinnata L., seed on Chang 
liver cell line 
 
S. No 
 
CONCENTRATION 
(µg/ml) 
%CELL VIABILITY 
 
SILYMARIN 
 
EEPPS 
1. 50 69.49 63.71 
2. 100 51.84 50.84 
3. 200 40.67 44.06 
4. 300 33.20 34.89 
5. 400 18.64 23.03 
6. 500 7.77 12.86 
7. Cell control 100 100 
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Figure. 5 
Cytotoxicity of Standard Silymarin and extract on Chang liver cell line 
       
 
                             
 
The cell viability decreased with increase in concentration in the case of Silymarin 
and EEPPS. The CTC50 values of the EEPPS was found to be 100µg/ml which is similar to 
that of the standard Silymarin. This indicates that the EEPPS is as safe as Silymarin against 
the normal Chang liver cell line. 
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6.3.1.2. In vitro hepatoprotective activity using Standard Silymarin and extract against 
CCl4 induced hepatotoxicity 
The Chang liver cells were first challenged with the CCl4 at the concentration of 
125µg/ml in which 39.92% cells are viable. Then the cells were treated with standard 
Silymarin and ethanolic extract of Pongamia pinnata L., seed in the concentration of 100, 50, 
25, 10µg/ml to assess the percentage cell viability and the values are tabulated in Table 3 
and Figure.6 
Table - 3 
In vitro hepatoprotective activity of Silymarin and EEPPS against CCl4 induced 
hepatotoxicity 
 
S. NO 
 
TREATMENT 
CONCENTRATION 
(µg/ml) 
% CELL 
VIABILITY 
1. Control  100 
2. CCl4 125 39.92±1.02 
 
3. 
CCl4 
+ 
Silymarin 
10 56.46±2.0 
25 61.9±2.3 
50 66.5±2.34 
100 72.2±2.1 
 
4. 
CCl4 
+ 
EEPPS 
10 50.3±0.54 
25 57.9±1.89 
50 65.2±2.32 
100 71.1±1.20 
 
Values are expressed as Mean ± S.D (n=3) 
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Figure. 6 
In vitro hepatoprotective activity of Silymarin and extract using 
CCl4 induced toxicity 
 
             
 In the Silymarin treated group, the cell viability was 72.2% at the highest 
concentration of 100µg/ml. The EEPPS group showed in cell viability of 71.2% which is 
relatively close to that of the standard Silymarin. This indicates that the EEPPS has 
hepatoprotective activity comparable with that of Silymarin. 
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The Cell morphology of the Chang liver cells of different group are shown in Figure.7 
Figure.7 
 
                                   
 a) Normal Chang cell                                                  b) Carbon tetrachloride 
                                 
   c) CCl4 + Silymarin                                                      d) CCl4 +Ethanol extract  
    
The normal polygonal cell structure is seen in Figure a. In the CCl4 treated group the 
polygonal cells have shrunk and appear round in shape indicating cytotoxicity. These changes 
are attenuated in the Silymarin and EEPPS groups. 
 
 
 
 
 
Results 
 
Institute of Pharmacology, MMC Page 54 
 
6.4. IN VIVO STUDIES 
6.4.1. IN VIVO HEPATOPROTECTIVE EVALUATION OF EEPPS USING CCl4 
MODEL OF HEPATOTOXICITY 
 Hepatoprotective activity 
Body weight 
The body weight of animals was determined on 1
st
 and 15
th
 day of the study period 
and these are tabulated in Table 4 and Figure.8 
Table - 4 
Body weight of animals in the various groups 
 
GROUPS TREATMENT 
 
ANIMAL BODY WEIGHT IN gms 
          1
st
 day             15
th
 day 
I Control 154.5±2.92 156±2.28 
II Disease control 158.2±2.19 156.5±2.85 
III Silymarin (25mg/kg) 156±3.85 155±3.54 
IV 
Pongamia pinnata L., 
(200mg/kg) 
157±2.29 156±2.49 
V 
Pongamia pinnata L., 
(400mg/kg) 
155.2±3.21 154.3±2.92 
 
Values are expressed as Mean ± S.D (n=6) 
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Figure. 8 
Body weight of animals in the various groups 
 
 
 
It is seen from the data that in the CCl4 treated group there was a slight decrease in 
body weight on the 15
th
 day as compared to 1
st
 day. In the Silymarin and EEPPS treated 
group the reduction in body was lesser than that of CCl4 group. 
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6.5. BIOCHEMICAL PARAMETERS 
6.5.1. Aspartate Aminotransferase (AST) evaluation  
The AST levels of the animals treated with CCl4 alone and those that were given CCl4 
and Silymarin/ EEPPS were estimated on Day 15. They are tabulated in Table 5 and 
Figure.9 
Table - 5 
GROUP TREATMENT AST (U/ml) 
I Control 84.8±3.62 
II Disease control 158±6.69٭ 
III Silymarin (25mg/kg) 94.5±4.03٭٭ 
IV 
Pongamia pinnata L., 
(200mg/kg) 
135±3.36٭٭ 
V 
Pongamia pinnata L., 
(400mg/kg) 
103±6.77٭٭ 
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭P<0.001 compared to disease control group. 
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Figure. 9 
AST levels 
 
 
 
It was seen that the AST levels had increased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the elevated levels of AST. The EEPPS treated groups of animals also showed a 
significant decrease in the elevated levels of AST. The reduction was more in the group 
treated with the higher dose (400mg/kg) of EEPPS. 
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6.5.2. Alanine Aminotransferase (ALT) evaluation 
The ALT levels of the animals treated with CCl4 alone and those that were given CCl4 
and Silymarin and EEPPS were estimated on Day 15.They are tabulated in Table 6 and  
Figure.10 
Table - 6 
 
 
          
 
 
 
 
 
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭P<0.001 compared to disease control group. 
 
 
 
 
 
 
 
 
 
GROUP TREATMENT ALT (U/ml) 
I Control 80.5±7.08 
II Disease control 182.6±14.4٭ 
III Silymarin (25mg/kg) 69.6±2.42٭٭ 
IV 
Pongamia pinnata L., 
(200mg/kg) 
96.3±6.34٭٭ 
V 
Pongamia pinnata L., 
(400mg/kg) 
83.3±2.92٭٭ 
Results 
 
Institute of Pharmacology, MMC Page 59 
 
Figure.10 
ALT levels 
 
 
 
It was seen that the ALT levels had increased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the elevated levels of ALT. The EEPPS treated groups of animals also showed a 
significant decrease in the elevated levels of ALT. The reduction was more in the group 
treated with the higher dose (400mg/kg) of EEPPS. 
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6.5.3. Alkaline Phosphatase (ALP) evaluation 
The ALT levels of the animals treated with CCl4 alone and those that were given CCl4 
and Silymarin/ EEPPS were estimated on Day 15. They are tabulated in Table 11and 
Figure.7 
 
Table - 7 
GROUP TREATMENT ALP (U/ml) 
I Control 138±9.42 
II Disease control 202±14.8٭ 
III Silymarin (25mg/kg) 110±10.4٭٭ 
 
IV 
Pongamia pinnata L., 
(200mg/kg) 
 
183±9.29٭٭٭ 
 
V 
Pongamia pinnata L., 
(400mg/kg) 
 
123.1±6.51٭٭ 
 
The values are expressed as mean ± S.D (n=6) 
٭ P<0.001 compared to control group. 
٭٭ P<0.001 compared to disease control. 
. ٭٭٭ P<0.05 compared to disease control. 
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Figure.11 
ALP levels 
 
 
 
It was seen that the ALP levels had increased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the elevated levels of ALP. The EEPPS treated groups of animals also showed a 
significant decrease in the elevated levels of ALP. The reduction was more in the group 
treated with the higher dose (400mg/kg) of EEPPS. 
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6.5.4. Total Bilirubin (TB) evaluation 
The Bilirubin levels of the animals treated with CCl4 alone and those that were given 
CCl4 and Silymarin/ EEPPS were estimated on Day 15. They are tabulated in Table 12 and 
Figure. 8 
Table - 8 
 GROUP TREATMENT TOTAL BILIRUBIN (gm/dl) 
I Control 0.41±0.66 
II Disease control 1.13±0.28٭ 
III Silymarin (25mg/kg) 0.83±0.07٭٭ 
 
IV 
Pongamia pinnata L., 
(200mg/kg) 
 
0.88±0.10٭٭ 
 
V 
Pongamia pinnata L., 
(400mg/kg) 
 
0.85±0.05٭٭ 
 
  
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭ P<0.05 compared to disease control. 
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Figure. 12 
Bilirubin levels 
             
 
 
  It was seen that the Bilirubin levels had increased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the elevated levels of Bilirubin. The EEPPS treated groups of animals also 
showed a significant decrease in the elevated levels of Bilirubin. The reduction was more in 
the group treated with the higher dose (400mg/kg) of EEPPS 
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6.5.5. Total Protein (TP) evaluation 
 The Total Protein levels of the animals treated with CCl4 alone and those that were 
given CCl4 and Silymarin/ EEPPS were estimated on Day 15
. 
They are tabulated in Table 13 
and Figure. 9 
Table - 9 
GROUP TREATMENT TOTAL PROTEIN (g/dl) 
I Control 7.58±0.24 
II Disease control 6.8±0.16٭ 
III Silymarin (25mg/kg) 6.95±0.28٭٭ 
IV 
Pongamia pinnata L., 
(200mg/kg) 
6.45±0.29٭٭ 
V 
Pongamia pinnata L., 
(400mg/kg) 
6.76±0.16٭٭ 
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭ P<0.05 compared disease group. 
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Figure. 13 
Total Protein levels 
 
 
                
       It was seen that the Total Protein levels had decreased significantly in animals which 
were given CCl4 as compared to normal group. Treatment with Silymarin showed a 
significant increase in the decreased levels of Total Protein. The EEPPS treated groups of 
animals also showed a significant increase in the decreased levels of Total Protein. The 
elevation was more in the group treated with the higher dose (400mg/kg) of EEPPS. 
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6.5.6. Albumin (ALB) evaluation 
The Total Protein levels of the animals treated with CCl4 alone and those that were 
given CCl4 and Silymarin/ EEPPS were estimated on Day 15
. 
They are tabulated in Table 10 
and Figure. 14 
Table - 10 
 
GROUP TREAMENT ALBUMIN (Grams) 
I Control 3.8±0.25 
II Disease control 3.5±0.18٭ 
III Silymarin (25mg/kg) 3.7±0.12٭٭ 
 
IV 
Pongamia pinnata L., 
(200mg/kg) 
 
3.6±0.1٭٭ 
 
V 
Pongamia pinnata L., 
(400mg/kg) 
 
3.7±0.12٭٭ 
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭P<0.05 compared to disease group. 
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Figure. 14 
Albumin levels 
 
 
              
       It was seen that the Albumin levels had decreased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
increase in the decreased levels of Albumin. The EEPPS treated groups of animals also 
showed a significant increase in the decreased levels of Albumin. The elevation was more in 
the group treated with the higher dose (400mg/kg) of EEPPS. 
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6.6. ESTIMATION OF ANTIOXIDANT ENZYMES LEVEL 
6.6.1.Lipid peroxidation (LPO) 
The Lipid peroxidase enzyme levels of the animals treated with CCl4 alone and those 
that were given CCl4 and Silymarin/ EEPPS were esimated in liver homogenised solution on 
Day15. They are tabulated in Table 11 and Figure. 15 
 
Table -11 
 
GROUP TREATMENT LPO (moles/100mg/Protein) 
I Control 2.25±0.07 
II Disease control 6.50±0.04٭ 
III Silymarin (25mg/kg) 4.98±0.09٭٭ 
IV Pongamia pinnata L., (200mg/kg) 5.55±0.39٭٭ 
V Pongamia pinnata L., (400mg/kg) 4.64±0.03٭٭ 
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭ P<0.001 compared disease group. 
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Figure. 15 
LPO levels 
 
 
 
   It was seen that the LPO levels had increased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
decrease in the elevated levels of LPO. The EEPPS treated groups of animals also showed a 
significant decrease in the elevated levels of LPO. The elevation was more in the group 
treated with the higher dose (400mg/kg) of EEPPS. 
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6.6.2. Superoxide Dismutase (SOD) 
 The Superoxide dismutase enzyme levels of the animals treated with CCl4 alone and 
those that were given CCl4 and Silymarin/ EEPPS were esimated in liver homogenised 
solution on Day15. They are tabulated in Table 12 and Figure.16 
                             
Table – 12 
 
GROUP TREATMENT SOD (Unit/min/mg of Protein) 
I Control 7.17±0.02 
II Disease control 5.91±0.03٭ 
III Silymarin (25mg/kg) 6.28±0.03٭٭ 
IV Pongamia pinnata L., (200mg/kg) 4.46±0.20٭٭ 
V Pongamia pinnata L., (400mg/kg) 5.58±0.03٭  
 
The values are expressed as mean ± S.D (n=6) 
٭P<0.001 compared to control group. 
٭٭P<0.001 compared disease group. 
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Figure. 16 
SOD levels 
 
    
It was seen that the SOD levels had decreased significantly in animals which were 
given CCl4 as compared to normal group. Treatment with Silymarin showed a significant 
increase in the decreased levels of SOD. The EEPPS treated groups of animals also showed a 
significant increase in the decreased levels of SOD. The elevation was more in the group 
treated with the higher dose (400mg/kg) of EEPPS. 
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6.7. The histopathology of the liver was carried out the photograph of the slides are 
given in Figure.17 
Figure. 17 
Histopathological studies of liver 
   
                                  
     
        Normal control                                                             CCl4 treated 
                                  
CCl4 + Silymarin 25mg/kg                                      CCl4 + Pongamia pinnata L., 200mg/kg 
 
 
CCl4 + Pongamia pinnata L., 400mg/kg 
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8. DISCUSSION 
 
Liver is an important organ involved in metabolism of many xenobiotics. It removes 
toxins from the body. It is also exposed to several drugs and xenobiotics which cause hepatic 
damage. In the present study hepatoprotective activity on the seeds of Pongamia pinnata L., 
was evaluated.  
 
In vitro studies are carried out to evaluate the safety of the drug under study before 
taking them up for in vivo evaluation. 
 
The in vitro toxicity study was conducted on the ethanolic extract of Pongamia 
pinnata L., seeds using normal Chang liver cell line. The Chang liver cell line is 
differentiated non-malignant liver epithelial cell of human origin. The studies indicate that 
the EEPPS is as safe as Silymarin both having the same CTC50 of approximately 100µg/ml 
which is a standard drug. 
 
After establishing the safety of EEPPS, in vitro hepatoprotective evaluation was done. 
In vitro studies with cultured cell lines or primary hepatocytes have proved to be promising 
methods to evaluate hepatoprotective activity. For this study, CCl4 mediated hepatotoxicity 
on Chang liver cell line was used. CCl4 is the most commonly used hepatotoxin in the study 
of free radical induced liver disease. 
 
For in vitro evaluation, the hepatoprotective activity of an agent can be established by 
MTT assay and also by observing the morphological changes in the cell. 
Discussion 
 
Institute Of Pharmacology, MMC Page 74 
 
For MTT assay different concentrations (10, 25, 50, 100µg/ml) of Silymarin and 
EEPPS were used. In the group challenged with CCl4, the cell viability was only 39.9%.The 
cell viability of the CCl4 and EEPPS treated group was 71.2 % the cell viability of the CCl4 
and Silymarin treated group which was 72.2%. These data established that the EEPPS has a 
good hepatoprotective activity which is comparable to Silymarin, the currently used 
hepatoprotective drug. So confirm the hepatoprotective activity of the EEPPS, In vivo studies 
was carried out using CCl4 induced hepatic damage in rats.  
 
CCl4 - induced hepatic injury is an experimental model widely used for the screening 
of hepatoprotective drugs. CCl4 undergoes a biotransformation by hepatic microsomal 
cytochrome P-450 to produce trichloromethyl free radicals. These hepatotoxic metabolite can 
react with protein and lipid in the membrane of cells or organelles leading to necrosis of 
hepatocytes. As a result of hepatic injury, permeability of the cell membrane is altered 
causing the cytosolic transaminase (ALT, AST) in the circulation. Hence evaluations of AST 
and ALT are definite indicators of hepatoprotective activity. The rise in the serum levels of 
ALP, AST, ALT and bilirubin as observed in the present study could be attributed to the 
damaged structural integrity of the liver. Liver damage is also associated with elevated levels 
of ALT, and Bilirubin. It is also associated with decrease in levels of Total Protein and 
Albumin. 
 
The administration of EEPPS at both doses 200mg/kg and 400mg/kg showed a 
improvement in the biochemical parameter profile of the animals. The effect seen with the 
higher dose is almost equal to that of the standard drug Silymarin. These evaluation study 
confirms the hepatoprotective potential of EEPPS. 
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It has been hypothesized that one of the principal causes of CCl4- induced liver injury 
is formation of lipid peroxidases by free radical derivatives of CCl4 (CCl3.). Thus, the 
antioxidant activity or the inhibition of the generation of free radicals is important in the 
protection against CCl4-induced hepatotoxicity. 
 
The body has an effective defence mechanism to prevent and neutralize the free 
radical-induced damage. This is accomplished by a set of endogenous antioxidant enzymes 
such as SOD, Catalase. SOD has been reported as one of the most important enzyme in the 
enzymatic antioxidant defense system. It scavenges the superoxide anion to form hydrogen 
peroxide and thus diminishing the toxic effect caused by this radical. Decrease in enzyme 
activity of superoxide dismutase (SOD) is a sensitive index in hepatocellular damage and is 
the most sensitive enzymatic index in live injury. The EEPPS causes a significant increase in 
hepatic SOD activity indicating a reduction of reactive free radical induced oxidative damage 
to liver. 
 
Lipid peroxidation has been implicated in the pathogenesis of hepatic injury by 
compounds like CCl4 and is responsible for cell membrane alteration. In the present study, 
elevated level of LPO observed in CCl4 administered rats indicated excessive formation of 
free radicals and activation of LPO system resulting in hepatic damage. Treatment with 
different dose levels of EEPPS significantly reversed these changes. Hence, it is possible that 
the mechanism of hepatoprotection of Pongamia pinnata L., might be due to its antioxidant 
action.  
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Histopathological liver sections also revealed that the hepatic architecture was altered 
by hepatotoxin in Carbon tetrachloride group, whereas in the liver sections of the rat treated 
with the EEPPS and intoxicated with CCl4, the hepatic architecture was not altered and was 
comparable with the standard drug Silymarin. The histopathological study confirms the 
significant hepatoprotective effect of ethanolic extract of Pongamia pinnata L., seeds 
especially at the dose 400mg/kg.    
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9. CONCLUSION 
  From the study it is concluded that 
 
 The ethanolic extract of the seeds of Pongamia pinnata L., showed in vitro 
hepatoprotective activity against CCl4 induced toxicity in Chang liver cell 
line. 
 The ethanolic extract of Pongamia pinnata L., seeds possesses promising 
hepatoprotective activity against CCl4 induced hepatic damage. The 
activity is more pronounced at a dose of 400mg/kg.  
 The activity could be due to improvement in the antioxidant enzyme levels 
and a decrease in free radical levels. The presences of phytochemicals such 
as flavonoids have been shown to be responsible for hepatoprotective 
activity.  
 Further studies can be carried out in the future to elucidate the mechanism 
of action of the ethanolic extract of seeds of Pongamia pinnata L., which 
may then be followed by and then clinical studies to establish its efficacy 
in humans. 
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